List of news
22/05/2013 Guerbet at ESGAR 2013
Palau de Congressos de Catalunya, Barcelona, Spain, June 4-7 2013
26/04/2013 Guerbet at ESPR 2013
Marriott Hotel, Budapest, Hungary, June 3-7 2013
25/04/2013 Registration Document 2012 available
The Registration Document is now available. You will also find it in the Investors section.
23/04/2013 2013 first-quarter revenue
Year's start impacted by the good performance in 2012 H2
21/03/2013 USA: FDA Approves Dotarem®
FDA Approves Dotarem® (gadoterate meglumine), first macrocyclic and ionic gadolinium-based contrast agent in USA
06/03/2013 2012 annual results
Sustained growth mainly from gains in the second half
15/02/2013 USA: Medical Imaging Drugs Advisory Committee Recommends Approval of Guerbet NDA for Dotarem
Guerbet announced that the Medical Imaging Drugs Advisory Committee to US Food and Drug Administration (FDA) has voted unanimously by votes of 17 to 0 to recommend that FDA approve the New Drug Application (NDA) for Dotarem® (gadoterate meglumine) for adults, and for pediatric use for children...